Unknown PHASE4 INTERVENTIONAL 2-arm NCT01151644

Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases

Sponsor: Fundação de Amparo à Pesquisa do Estado de São Paulo

Conditions Antiphospholipid Syndrome DMixed Connective Tissue Disease Dermatomyositis (DM) Juvenile DM Juvenile Idiopathic Arthritis Juvenile SLE Rheumatoid Arthritis Sjögren's Syndrome Spondyloarthritis Systemic Lupus Erythematosus (SLE) Systemic Sclerosis (SSc) Systemic Vasculitis

Interventions Anti-pandemic H1N1 influenza vaccine

Updated 5 times since 2017 Last updated: Jun 25, 2010 Started: Apr 30, 2010 Primary completion: Jul 31, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Antiphospholipid Syndrome and DMixed Connective Tissue Disease, this trial is ongoing. The trial is conducted by Fundação de Amparo à Pesquisa do Estado de São Paulo and has accumulated 5 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE4
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE4

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundação de Amparo à Pesquisa do Estado de São Paulo
University of Sao Paulo

Data source: University of Sao Paulo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São Paulo, Brazil